4 results match your criteria: "Centre national de référence maladies auto-inflammatoires et amylose[Affiliation]"
Guselkumab in Behçet's disease.
Ann Rheum Dis
November 2024
Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Auto-immunes Systémiques Rares, Centre National de Référence Maladies Auto-inflammatoires et Amylose Inflammatoire, Hôpital Universitaire Pitié-Salpêtrière, Paris, France
Efficacy and safety of steroid-sparing treatments in giant cell arteritis according to the glucocorticoids tapering regimen: A systematic review and meta-analysis.
Eur J Intern Med
June 2021
Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR-S 1136, AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Paris, France. Electronic address:
Objectives: To assess the efficacy and safety of adjuvant therapies in newly diagnosed or relapsing giant cell arteritis (GCA) in terms of relapse rate at week 52 (primary outcome) and to assess the impact of GC tapering regimen on adjuvant effectiveness.
Methods: For this systematic review and meta-analysis, we searched PubMed, EMBASE, CENTRAL, trial registries, from inception to November 2020. We included all randomized controlled trials (RCTs) and controlled prospective studies evaluating adjuvant treatments in GCA, without date or language restriction.
Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals.
Therap Adv Gastroenterol
July 2020
Department of Internal Medicine and Clinical Immunology, Hôpital La Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Cedex 13, Paris, France.
Article Synopsis
- * Symptomatic cryoglobulinemia vasculitis (CV) affects 5-10% of those with HCV-related cryoglobulinemia and can cause serious health complications due to small-vessel inflammation, manifesting in skin, joints, nerves, and kidneys.
- * Direct-acting antivirals (DAA) have transformed the treatment of chronic HCV, achieving over 95% success rates and notably improving symptoms associated with CV.
Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.
J Autoimmun
July 2020
Department of Internal Medicine and Clinical Immunlogy, Sorbonne Université, Pitié-Salpêtrière University Hospital, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de référence maladies auto-immunes systémiques rares, Centre national de référence maladies auto-inflammatoires et amylose, INSERM UMR_S 959, Immunologie-Immunopathologie-Immunothérapie, i3, France. Electronic address:
Purpose: Drug-induced uveitis is a rare but sight-threatening condition. We seek to determine the spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors (ICI).
Methods: Retrospective pharmacovigilance study based on adverse drug reactions reported within VigiBase, the WHO international pharmacovigilance database.